07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

ACH-3102: Additional Phase IIa data

Additional data from 8 treatment-naïve patients with HCV genotype 1b infection carrying the CC genotype of the interleukin-28B (IL-28B; IFNL3 ) gene in an open-label Phase IIa trial showed that oral ACH-3102 plus ribavirin for...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

BIT225: Interim Phase II data

Interim data from 12 treatment-naïve patients co-infected with HIV and chronic HCV genotype 1 or 3 infection in an open-label, Thai Phase II trial showed that all 6 patients with HCV genotype 3 infection who...
07:00 , Aug 19, 2013 |  BC Week In Review  |  Company News

Biosurfit S.A., Epistem, Qlucore AB, French National Institute of Health and Medical Research (INSERM), Inserm Transfert Initiative diagnostics news

Epistem said it received a three-year €1.5 million ($2 million) award from the EU's Framework Programme 7 (FP7) as part of a €6 million ($8 million) award for the PoC-HCV consortium project to develop point-of-care...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Deleobuvir: Additional Phase IIb data

Additional data from the open-label, international Phase IIb SOUND-C3 trial showed that 19 of 20 (95%) evaluable treatment-naïve patients with chronic HCV genotype 1b infection who received once-daily faldaprevir (BI 201335) plus twice-daily deleobuvir (BI...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Clinical News

Faldaprevir: Additional Phase IIb data

Additional data from the open-label, international Phase IIb SOUND-C3 trial showed that 19 of 20 (95%) evaluable treatment-naïve patients with chronic HCV genotype 1b infection who received once-daily faldaprevir (BI 201335) plus twice-daily deleobuvir (BI...
07:00 , May 6, 2013 |  BC Week In Review  |  Clinical News

Simeprevir: Additional Phase III data

Medivir reported subgroup data from the double-blind, placebo-controlled, international Phase III QUEST-2 trial in 391 treatment-naive patients with HCV genotype 1 infection evaluating once-daily 150 mg oral simeprevir for 12 weeks plus Pegasys peginterferon alfa-2a...
07:00 , May 6, 2013 |  BC Week In Review  |  Clinical News

Simeprevir: Additional Phase III data

Medivir reported subgroup data from the double-blind, placebo-controlled, international Phase III QUEST-1 trial in 394 treatment-naive patients with HCV genotype 1 infection evaluating once-daily 150 mg oral simeprevir for 12 weeks plus Pegasys peginterferon alfa-2a...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

Incivek telaprevir: Interim Phase IIIb data

Interim data from 85 evaluable patients in the 12-week treatment arm of the open-label, placebo-controlled, international Phase IIIb CONCISE trial showed that twice-daily 1,125 mg Incivek plus peginterferon and ribavirin for 12 weeks led to...
07:00 , Apr 29, 2013 |  BC Week In Review  |  Clinical News

ACH-3102: Additional Phase IIa data

Data from all 8 treatment-naïve patients with HCV genotype 1b infection carrying the CC genotype of the interleukin-28B (IL-28B; IFNL3 ) gene in an open-label Phase IIa trial showed that oral ACH-3102 plus ribavirin for...
08:00 , Jan 14, 2013 |  BC Week In Review  |  Clinical News

ACH-3102: Interim Phase IIa data

Interim data from 5 evaluable patients in an open-label Phase IIa trial showed that oral ACH-3102 plus ribavirin led to an RVR, defined as HCV RNA levels <25 IU/mL at week 4, in 80% of...